Rhythm Pharmaceuticals Q3 2026 Results: Net Loss of $41.4M, Loss Narrows
Rhythm Pharmaceuticals reported total revenues of $223.5 million for the nine months ended September 30, 2026, a significant increase from $132.5 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $146.3 million due to increased selling, general, and administrative expenses and research and development costs.
- Key figure
- Net loss $41.4M